What we do here
changes lives everywhere.
When you follow the science, one thing leads to another. A new insight takes a previous breakthrough further. And what we learn about cancer we turn against cancer.
What we do here
Some of the scientists and patients continuing Dana‑Farber’s momentum of cancer discovery.
Anthony G. Letai, MD, PhD; John K., patient; Elyahs J., patient; Jacqueline Garcia, MD
Identifying BCL-2 as a protein cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, which has become a powerful agent in the fight against CLL and AML.
Pasi A. Jänne, MD, PhD; Ryan F., patient
Identifying the EGFR mutation leads to the first broad application of precision medicine in lung cancer – which is paving the way for other active targeted lung cancer therapies.
F. Stephen Hodi, Jr., MD; Naftali I., patient; Gordon J. Freeman, PhD
Combining treatments of the PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.
William G. Kaelin Jr., MD; Chuck S., patient
Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.
Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.
What’s the story behind some of Dana-Farber’s most remarkable discoveries? This podcast series takes you deeper.
Explore the latest Dana-Farber advances in cancer medicine designed for medical professionals.
